NDAINJECTIONINJECTABLE
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
NOVANTRONE (mitoxantrone hydrochloride) by Fresenius Kabi is clinical pharmacology: mechanism of action mitoxantrone, a dna-reactive agent that intercalates into deoxyribonucleic acid (dna) through hydrogen bonding, causes crosslinks and strand breaks. First approved in 1987.
Drug data last refreshed 19h ago
Mechanism of Action
CLINICAL PHARMACOLOGY: Mechanism of Action Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an…
Worked on NOVANTRONE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.